Abstract: Parasitic egress and invasion-associated genes and their encoded proteins (referred to as “EIAGs,”) and compositions and methods of use there, including in vaccines and targets for treatment of parasitic infections are provided.

Abstract: Compositions and methods for enriching, isolating, and/or detecting SARS-CoV-2 RNA in a sample are provided. The compositions include the nucleocapsid (N) protein derived from SARS-CoV-2 virus, or a functional fragment or variant thereof, preferably having one or both of R203K and G204R mutations. The compositions are brought in contact with a sample obtained from a subject. The disclosed compositions can be use in methods of detecting SARS-CoV-2 nucleic acids in a sample such as mucus, sputum (processed or unprocessed), bronchial alveolar lavage (BAL), bronchial wash (BW), bodily fluids, cerebrospinal fluid (CSF), urine, tissue (e.g., biopsy material), rectal swab, nasopharyngeal aspirate, nasopharyngeal swab, throat swab, feces, plasma, serum, or whole blood, thus, methods of detecting SARS-CoV-2 in such samples are also provided.

Abstract: Compositions and methods for generating an immune response to fight against viral infections such as SARS-CoV-2 are provided. The disclosed compositions and methods are based on the discovery of the three consecutive SNPs (G28881A, G28882A, G28883C) underlying the R203K/G204R mutation in the SARS-CoV-2 N protein, associated with increased immune system response when expressed in cells. The immune responses that can be upregulated by the disclosed compositions include antibody production and/or upregulation of immune related genes that are generally involved in host defense against viral and bacterial infections, for example, increased expression of one or more genes including, but not limited to SHFL, MX1, AMD9L, TRIM22, TRIM14, EIF2 AK2, etc. The compositions include a peptide of the SARS-CoV-2 N-protein including the R203K/G204R mutation, a fragment thereof, or a nucleic acid encoding the same. The compositions are administered to a subject in need thereof to elicit an immune response in the subject.

Abstract: Oligonucleotides for use in amplifying at least one gene present in M. riyadhense are disclosed. The oligoncleotides include forward primers, SEQ ID NO:1, 3, 5, and 7 and the reverse primers comprises, consists essentially of or consists of SEQ ID NO:2, 4, 6, and 8, fragment(s), derivative(s), mutation(s), or complementary sequence(s) thereof. Also provided are methods for detecting the presence of M. riyadhense in a sample. The method includes contacting a biological sample with a pair of forward/reverse primers, under conditions suitable for amplification of at least one gene product from M. riyadhense if present in a sample and detecting the presence of the amplification product. The oligonucleotides and method disclosed herein can be used to determine the presence of M. riyadhense in a biological or non-biological sample. The sample can be obtained from a subject such as a human subject.

Abstract: Oligonucleotides for use in amplifying at least one gene present in M. riyadhense are disclosed. The oligoncleotides include forward primers, SEQ ID NO:1, 3, 5, and 7 and the reverse primers comprises, consists essentially of or consists of SEQ ID NO:2, 4, 6, and 8, fragment(s), derivative(s), mutation(s), or complementary sequence(s) thereof. Also provided are methods for detecting the presence of M. riyadhense in a sample. The method includes contacting a biological sample with a pair of forward/reverse primers, under conditions suitable for amplification of at least one gene product from M. riyadhense if present in a sample and detecting the presence of the amplification product. The oligonucleotides and method disclosed herein can be used to determine the presence of M. riyadhense in a biological or non-biological sample. The sample can be obtained from a subject such as a human subject.

Abstract: Provided herein are immunogenic compositions against Plasmodium, comprising an immunogenic polypeptide. Also provided are methods of immunizing a subject against Plasmodium, methods of eliciting an immune response in a subject against Plasmodium, and methods of identifying parasite genes driving medically important selectable phenotypes.